To assess the associations of semaglutide with recurrent CUD, the study population included 2034 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications during 6/202112/2022 (time zero or index event), had a diagnosis of CUD on or before the index event, and had a diagnosis of at least one of obesity-associated comorbidities on or before the index event
Lilly has also argued that the presence of compounded products in the supply chain makes it harder for patients to ensure they buy a legally produced version, as the market has been flooded with illicit copies
Patients following such a diet, should be advised to take oral vitamin B12 regularly
If they do, this would also add evidence that this NNMT inhibitor improves muscle performance through increasing NAD+ levels
Always consult your healthcare provider before making changes to your nutrition, exercise, supplement routine, or GLP-1 medication plan.